

Resource Summary Report

Generated by [kravitz2](#) on Jul 31, 2026

Critical Path Institute; Arizona; USA

RRID:SCR_011173

Type: Tool

Proper Citation

Critical Path Institute; Arizona; USA (RRID:SCR_011173)

Resource Information

URL: <http://c-path.org/>

Proper Citation: Critical Path Institute; Arizona; USA (RRID:SCR_011173)

Description: An independent, non-profit organization dedicated to bringing scientists from the FDA, industry and academia all together to collaborate and improve the drug development and regulatory process for medical products.

Abbreviations: C-Path

Synonyms: Critical Path Institute

Resource Type: institution

Resource Name: Critical Path Institute; Arizona; USA

Resource ID: SCR_011173

Alternate IDs: nlx_157876, Wikidata: Q5186651, grid.417621.7

Alternate URLs: <https://ror.org/02mgtg880>

Record Creation Time: 20220129T080302+0000

Record Last Update: 20260725T190713+0000

Ratings and Alerts

No rating or validation information has been found for Critical Path Institute; Arizona; USA.

No alerts have been found for Critical Path Institute; Arizona; USA.

Data and Source Information

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Nedelman J, et al. (2025) Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials. *IJTLD open*, 2(8), 464.

Starling MS, et al. (2025) The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making. *Clinical pharmacology and therapeutics*, 117(2), 343.

Wilk J, et al. (2025) A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies. *CPT: pharmacometrics & systems pharmacology*, 14(11), 1787.

Rutherford KM, et al. (2024) PomBase: a Global Core Biodata Resource-growth, collaboration, and sustainability. *Genetics*, 227(1).

Sundquist Beauman S, et al. (2023) Nurses' Knowledge, Communication Needs, and Future Directions in Neonatal Research: Results of an International Survey. *Advances in neonatal care : official journal of the National Association of Neonatal Nurses*, 23(4), 338.

Stephenson D, et al. (2022) Can Innovative Trial Designs in Orphan Diseases Drive Advancement of Treatments for Common Neurological Diseases? *Clinical pharmacology and therapeutics*, 111(4), 799.

Lyons MA, et al. (2021) Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design. *CPT: pharmacometrics & systems pharmacology*, 10(3), 211.

Chalkou K, et al. (2021) A two-stage prediction model for heterogeneous effects of treatments. *Statistics in medicine*, 40(20), 4362.

, et al. (2020) Abstract: Posters: 13th Clinical Trials on Alzheimer's Disease (CTAD) November 4-7, 2020. *The journal of prevention of Alzheimer's disease*, 7(S1), S55.

Shahin MH, et al. (2020) Open Data Revolution in Clinical Research: Opportunities and Challenges. *Clinical and translational science*, 13(4), 665.

Soul JS, et al. (2019) Recommendations for the design of therapeutic trials for neonatal seizures. *Pediatric research*, 85(7), 943.

Salaets T, et al. (2019) Development of a neonatal adverse event severity scale through a Delphi consensus approach. *Archives of disease in childhood*, 104(12), 1167.

Fostel JM, et al. (2008) Towards standards for data exchange and integration and their impact on a public database such as CEBS (Chemical Effects in Biological Systems). *Toxicology and applied pharmacology*, 233(1), 54.